Immunomedics, Inc. (IMMU) Receives Consensus Recommendation of “Buy” from Analysts
Shares of Immunomedics, Inc. (NASDAQ:IMMU) have been assigned a consensus rating of “Buy” from the six brokerages that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating on the company. The average 12-month price target among brokers that have covered the stock in the last year is $15.50.
Several analysts recently issued reports on IMMU shares. Jefferies Group boosted their price objective on shares of Immunomedics from $11.00 to $14.00 and gave the company a “buy” rating in a report on Tuesday, September 19th. Zacks Investment Research upgraded shares of Immunomedics from a “hold” rating to a “buy” rating and set a $15.00 price objective on the stock in a report on Wednesday, October 4th. ValuEngine lowered shares of Immunomedics from a “hold” rating to a “sell” rating in a report on Monday, December 4th. Finally, BidaskClub upgraded shares of Immunomedics from a “hold” rating to a “buy” rating in a report on Friday, December 22nd.
Shares of Immunomedics (IMMU) traded down $0.66 on Tuesday, reaching $15.85. 2,003,266 shares of the company traded hands, compared to its average volume of 3,880,000. The stock has a market cap of $2,410.00, a price-to-earnings ratio of -7.08 and a beta of 1.48. Immunomedics has a 12-month low of $3.83 and a 12-month high of $17.24. The company has a debt-to-equity ratio of -0.29, a quick ratio of 0.74 and a current ratio of 0.74.
In other Immunomedics news, Director Brian A. Markison sold 8,390 shares of Immunomedics stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $11.89, for a total value of $99,757.10. Following the completion of the transaction, the director now directly owns 99,178 shares of the company’s stock, valued at approximately $1,179,226.42. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Venbio Select Advisor Llc bought 1,150,000 shares of the company’s stock in a transaction on Tuesday, November 14th. The stock was purchased at an average cost of $10.39 per share, with a total value of $11,948,500.00. The disclosure for this purchase can be found here. 6.60% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. FMR LLC grew its position in Immunomedics by 260.6% in the 2nd quarter. FMR LLC now owns 5,496,851 shares of the biopharmaceutical company’s stock valued at $48,537,000 after acquiring an additional 3,972,388 shares in the last quarter. State Street Corp grew its position in Immunomedics by 37.2% in the 2nd quarter. State Street Corp now owns 4,818,847 shares of the biopharmaceutical company’s stock valued at $42,549,000 after acquiring an additional 1,305,298 shares in the last quarter. Vanguard Group Inc. grew its position in Immunomedics by 2.4% in the 2nd quarter. Vanguard Group Inc. now owns 4,522,091 shares of the biopharmaceutical company’s stock valued at $39,930,000 after acquiring an additional 105,558 shares in the last quarter. Farallon Capital Management LLC grew its position in Immunomedics by 1.7% in the 2nd quarter. Farallon Capital Management LLC now owns 4,227,500 shares of the biopharmaceutical company’s stock valued at $37,329,000 after acquiring an additional 72,500 shares in the last quarter. Finally, Palo Alto Investors LLC acquired a new position in Immunomedics in the 2nd quarter valued at about $26,582,000. 76.28% of the stock is owned by institutional investors.
Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.
Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.